Cited by 188Cancer-related gene regulationGlioma Diagnosis and TreatmentRNA modifications and cancer

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma

Open access

Yan, Fengting, Alinari, Lapo, Lustberg, Mark E., Katherine Martin, Ludmila, Cordero-Nieves, Hector M., Banasavadi-Siddegowda, Yeshavanth, Virk, Selene, Barnholtz-Sloan, Jill, Bell, Erica Hlavin, Wojton, Jeffrey, Jacob, Naduparambil K., Chakravarti, Arnab, Nowicki, Michal O., Wu, Xin, Lapalombella, Rosa, Datta, Jharna, Yu, Bo, Gordon, Kate, Haseley, Amy, Patton, John T., Smith, Porsha L., Ryu, John, Zhang, Xiaoli, Mo, Xiaokui, Marcucci, Guido, Nuovo, Gerard, Kwon, Chang-Hyuk, Byrd, John C., Chiocca, E. Antonio, Li, Chenglong, Sif, Said, Jacob, Samson, Lawler, Sean, Kaur, Balveen, Baiocchi, Robert A.·2014·Cancer Research

DOI 10.1158/0008-5472.can-13-0884PMC PMC3959215

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Glioblastoma is the most common and aggressive histologic subtype of brain cancer with poor outcomes and limited treatment options. Here, we report the selective overexpression of the protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. PRMT5 silences the transcription of regulatory genes by catalyzing symmetric dimethylation of arginine residues on histone tails. PRMT5 overexpression in patient-derived primary tumors and cell lines correlated with cell line growth rate and inversely with overall patient survival. Genetic attenuation of PRMT5 led to cell-cycle arrest, apoptosis, and loss of cell migratory activity. Cell death was p53-independent but caspase-dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of care. Global gene profiling and chromatin immunoprecipitation identified the tumor suppressor ST7 as a key gene silenced by PRMT5. Diminished ST7 expression was associated with reduced patient survival. PRMT5 attenuation limited PRMT5 recruitment to the ST7 promoter, led to restored expression of ST7 and cell growth inhibition. Finally, PRMT5 attenuation enhanced glioblastoma cell survival in a mouse xenograft model of aggressive glioblastoma. Together, our findings defined PRMT5 as a candidate prognostic factor and therapeutic target in glioblastoma, offering a preclinical justification for targeting PRMT5-driven oncogenic pathways in this deadly disease. Cancer Res; 74(6); 1752–65. ©2014 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-0884

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citation
Malignant Gliomas in Adults
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after Surgery
WALKER, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,618
The Bcl-2 family: roles in cell survival and oncogenesis
Cory, S., Huang, D. C. S., & Adams, J. M. (2003) · Oncogene · doi:10.1038/sj.onc.1207102 · Cited by 1,474
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Patre, P.-L. D., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,306
Control of mitochondrial apoptosis by the Bcl-2 family
Brunelle, J. K., & Letai, A. G. (2009) · Journal of Cell Science · doi:10.1242/jcs.031682 · Cited by 928
Human SWI/SNF-Associated PRMT5 Methylates Histone H3 Arginine 8 and Negatively Regulates Expression of ST7 and NM23 Tumor Suppressor Genes
Pal, S., Vishwanath, S. N., Erdjument‐Bromage, H., Tempst, P., & Sif, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9630-9645.2004 · Cited by 599
Self-citation
PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing
Zhao, Q., Rank, G., Tan, Y., Li, H., Moritz, R. L., Simpson, R. J., Cerruti, L., Curtis, D. J., Patel, D. J., Allis, C. D., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1568 · Cited by 539

Show all 40 references

Sorted by citations

Items 101–188 of 188

PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Kumar, D., Jain, S., Coulter, D. W., Joshi, S. S., & Chaturvedi, N. K. (2023) · Cancers · doi:10.3390/cancers15245855 · Cited by 16
Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies
Muzyka, L., Goff, N. K., Choudhary, N. R., & Koltz, M. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310456 · Cited by 15
Aflatoxin-induced upregulation of protein arginine methyltransferase 5 is mediated by protein kinase C and extracellular signal-regulated kinase
Ghufran, M. S., Soni, P., & Kanade, S. R. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-018-9439-8 · Cited by 14
Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib
Banasavadi‐Siddegowda, Y., Namagiri, S., Otani, Y., Sur, H. P., Rivas, S. R., Bryant, J.-P., Shelbourn, A., Rock, M. B., Chowdhury, A. K., Lewis, C. T., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac095 · Cited by 14
Self-citation
Aflatoxin B1 induced upregulation of protein arginine methyltransferase 5 in human cell lines
Ghufran, M. S., Ghosh, K., & Kanade, S. R. (2016) · Toxicon · doi:10.1016/j.toxicon.2016.05.015 · Cited by 14
Histone modifiers at the crossroads of oncolytic and oncogenic viruses
Murphy, S. A., Mapes, N. J., Dua, D., & Kaur, B. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.006 · Cited by 13
Self-citation
Combined inhibition by PRMT5 and MAT2A demonstrates a strong synthetic lethality in MTAP homozygous-deficient glioma models
Jiang, Z., Li, X., Xiao, Z., Gan, W., Zhang, X., Zhang, Y., Wang, W., Qinzhi, E., Huang, Y., Shi, Q., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02545-2 · Cited by 14
Self-citation
Advancing lymph node metastasis in head and neck squamous cell carcinoma: Integrative mechanisms, emerging diagnostics, and translational therapies
Cai, Q., Cai, W., Liu, Y., Li, M., Xiang, S.-E., Ji, H., Zhang, Z., Yu, N., Hu, Y., Hu, Y., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104854 · Cited by 13
Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis
Liang, Z., Liu, L., Wen, C., Jiang, H., Ye, T., Ma, S., & Liu, X. (2021) · Cancer Control · doi:10.1177/10732748211050583 · Cited by 13
Characterization of the Kinetic Mechanism of Human Protein Arginine Methyltransferase 5
Eddershaw, A., Stubbs, C. J., Edwardes, L. V., Underwood, E., Hamm, G. R., Davey, P. R. J., Clarkson, P. N., & Syson, K. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00554 · Cited by 12
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia
Johanssen, T., McVeigh, L. E., Erridge, S., Higgins, G. S., Straehla, J. P., Frame, M. C., Aittokallio, T. A., Carragher, N. O., & Ebner, D. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1075559 · Cited by 10
Basic Epigenetic Mechanisms
Davie, J., Sattarifard, H., Sudhakar, S. R. N., Roberts, C.-T., Beacon, T. H., Muker, I., Shahib, A. K., & Rastegar, M. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-75980-2_1 · Cited by 12
Arginine methylation in cancer: mechanisms and therapeutic implications
Xu, Y., Wu, Q., Zhang, Y., Gu, Y., Zhu, H., Fu, X., Li, A., & Li, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00860-5 · Cited by 13
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
Sloan, S. L., Renaldo, K. A., Long, M., Chung, J.-H., Courtney, L. E., Shilo, K., Youssef, Y., Schlotter, S. Y., Brown-Burke, F., Klamer, B. G., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250839 · Cited by 10
Self-citation
Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5
Zhang, Q., Yang, R., Tian, Y., Ge, S., Nan, X., Zhu, S., Dong, S., & Zhang, B. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13736 · Cited by 10
PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RARα
Huang, X., Yang, Y., Zhu, D., Zhao, Y., Wei, M., Li, K., Zhu, H., & Zheng, X. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04358-3 · Cited by 10
The Role of Chromatin-Associated Proteins in Cancer
Helin, K., & Minucci, S. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034422 · Cited by 9
The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article
Azab, M. A. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040018 · Cited by 9
Glioblastoma with PRMT5 gene upregulation is a key target for tumor cell regression
Kurdi, M. E., Fadul, M. M., Addas, B. M. J., Faizo, E., Bamaga, A. K., Alsinani, T., Katib, Y., Alkhotani, A., Fathaddin, A., Turkistani, A. N., et al. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2023-0534 · Cited by 8
Protein arginine methyltransferase 5 as a novel therapeutic target in solid tumors
Song, P., & Yang, F. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101796 · Cited by 7
Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors
Chen, Y., Shi, Q., Yang, H. J., Li, J., Zhou, K., Zhang, J., Wang, Z., Shi, H., Xiong, B., Liu, J., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106228 · Cited by 7
Protein arginine methyltransferases as regulators of cellular stress
Zaccarelli‐Magalhães, J., Citadin, C. T., Langman, J., Smith, D. J., Matuguma, L. H., Lin, H. W., & Udo, M. S. B. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.115060 · Cited by 6
Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin’s Lymphoma
Li, Q., Xu, Q., Wang, Z., Qiao, N., Ni, X.-F., Jing, X., Zhou, S., Tian, X.-L., Zheng, G., Zhan, K.-N., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01548 · Cited by 7
Self-citation
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo
Brown, E. J., Balaguer‐Lluna, L., Cribbs, A. P., Philpott, M., Campo, L., Browne, M., Wong, J. F., Oppermann, U. C. T., Carcaboso, A. M., Bullock, A. N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-48652-x · Cited by 8
ZNF224 Protein: Multifaceted Functions Based on Its Molecular Partners
Cesaro, E., Lupo, A., Rapuano, R., Pastore, A., Grosso, M., & Costanzo, P. (2021) · Molecules · doi:10.3390/molecules26206296 · Cited by 7
Protein Arginine Methyltransferases from Regulatory Function to Clinical Implication in Central Nervous System
Xie, B., Yu, J., Chen, C., & Shen, T. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01546-0 · Cited by 8
Surface water extracts impair gene profiles and differentiation in human mesenchymal stem cells
Zhang, Z., Liu, W., Jun-xiang, H., Qu, Y., Zhao, J., Pan, Y., Zhang, X., & Quan, X. (2019) · Environment International · doi:10.1016/j.envint.2019.05.017 · Cited by 6
Self-citation
Dysregulated YY1/PRMT5 axis promotes the progression and metastasis of laryngeal cancer by targeting Hippo pathway
Wang, N., Wu, D., Qian, L., Yan, Y., Chen, X., Zhao, Z., Yan, H., Zhang, X., Xu, M., Deng, W., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16156 · Cited by 6
Self-citation
Inhibition of epigenetic and cell cycle-related targets in glioblastoma cell lines reveals that onametostat reduces proliferation and viability in both normoxic and hypoxic conditions
Lavõgina, D., Krõlov, M. K., Vellama, H., Modhukur, V., Nisio, V. D., Lust, H., Eskla, K., Salumets, A., & Jaal, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54707-4 · Cited by 4
PRMT5/WDR77 Enhances the Proliferation of Squamous Cell Carcinoma via the ΔNp63α-p21 Axis
Liang, H., Fisher, M. L., Wu, C., Ballon, C., Sun, X. S., & Mills, A. A. (2024) · Cancers · doi:10.3390/cancers16223789 · Cited by 5
Targeting PRMT5 enhances the radiosensitivity of tumor cells grown in vitro and in vivo
Degorre, C., Lohard, S., Bobrek, C. N., Rawal, K., Kuhn, S., & Tofilon, P. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-68405-8 · Cited by 4
New insight into targeting the DNA damage response in the treatment of glioblastoma
Tengfei, Z. H. E. N., Sun, T., XIONG, B., Liu, H., Wang, L., Chen, Y., & Sun, H. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60694-1 · Cited by 5
Discovery of Novel PRMT5 Inhibitors Bearing a Methylpiperazinyl Moiety
Bai, X., Zhai, Z., Zhao, X., Li, R., Liang, L., Jin, Y., & Yin, Y. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0244 · Cited by 4
CRL4DCAF4 E3 ligase-mediated degradation of MEN1 transcriptionally reactivates hTERT to sustain immortalization in colorectal cancer cells
Ao, Z., Xiao, D., Wu, J., Sun, J., & Liu, H. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae024 · Cited by 3
Use of Protein Arginine Methyltransferase Inhibitors in Gliomas
Harbi, E., & Mason, C. E. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00518 · Cited by 3
Antitumor Effects of PRMT5 Inhibition in Sarcomas
Verbeke, S., Bourdon, A., Guégan, J., Leroy, L., Chaire, V., Richard, É., Bessede, A., & Italiano, A. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0239 · Cited by 3
The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory
Kurdi, M. E., Alkhotani, A., Sabbagh, A. J., Faizo, E., Lary, A., Bamaga, A. K., Almansouri, M., Hafiz, B., Alsharif, T. H., & Baeesa, S. S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.051112 · Cited by 3
Drug discovery targeting protein arginine methyltransferase 5 (PRMT5): an update
Gu, Z., Kong, W., Liu, X., Hu, L., Zhou, Y., Liang, Z., Zhang, M., Chen, D., Li, F., & Chen, W. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118240 · Cited by 4
IRX1 is a novel gene, overexpressed in high-grade IDH-mutant astrocytomas
Sugur, H. S., Rao, S. J., Palavalasa, S., Menon, K. A., Arivazhagan, A., Mehta, B., & Santosh, V. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154464 · Cited by 3
Misregulation of Histone Methylation Regulators in Cancer
Ooi, W. F., Yao, X., Tan, P. B. O., & Teh, B. T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_8 · Cited by 3
The Role of Protein Arginine Methylation as a Post-Translational Modification in Cellular Homeostasis and Disease
Li, K., Xia, Q. J., Li, K., Yan, W., & Wang, C. (2025) · Biology · doi:10.3390/biology14101370 · Cited by 2
PRMT5 inhibition impairs Fanconi Anemia pathway-mediated homologous recombination and enhances the antitumor efficacy of Temozolomide in glioblastoma
Onishi, S., Jayamohan, S., Chowdhury, A. K., Rivas, S. R., Otani, Y., Ertekin, C., Bryant, J.-P., Murphy, S. A., Rivera-Caraballo, K., Walbridge, S., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08739-5 · Cited by 2
Self-citation
Identification of METTL3 and PRMT5 as an oncogenic pair for the prognosis and therapeutic targets of colorectal cancer subtype
Zhao, Q., Li, S., Chen, A., Zhu, S., Zhong, J., Zhang, P., She, Y.-L., Chen, R., Liu, W., & Wang, Y. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02144-7 · Cited by 2
Lessons learned from evolving frameworks in adult glioblastoma
Lechpammer, M., Mahammedi, A., Krummel, D. A. P., & Sengupta, S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00011-0 · Cited by 2
Recent news in the glioblastoma research
Rybalkina, E. Y., Pavlova, G. V., & Stavrovskaya, A. A. (2015) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747814060063 · Cited by 2
Highlights from the Literature
Huse, J. T., Abounader, R., Purow, B. W., Hegi, M. E., Soffietti, R., & Aldape, K. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now215 · Cited by 2
Regulation of RORα Stability through PRMT5-Dependent Symmetric Dimethylation
Xiong, G., Obringer, B., Jones, A., Horton, E., & Xu, R. (2024) · Cancers · doi:10.3390/cancers16101914 · Cited by 1
Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma
Nguyen, T. T. T., Yi, E. S., & Badr, C. E. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030027 · Cited by 1
ST7 binds YBX1 to suppress MMP14 expression and inhibit metastasis in non-small cell lung cancer
Qin, Y., Chen, Y., Cao, Q., Zhang, B., & Wan, Y. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112554 · Cited by 1
Actitud de los odontológos generales de Murcia en relación con la biopsia oral
López‐Jornet, P., Nicolás, A. P. V., Beneyto, Y. M., & Soria, M. F. (2007) · Medicina oral, patología oral y cirugía bucal · Cited by 1
Targeting protein arginine methylation to death
Miller, J. J. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab123 · Cited by 1
PRMT5-exacerbating tumor stemness and immunosuppression confer a novel immunotherapeutic vulnerability in aggressive prostate cancerPreprint
Zou, C., Xu, B., Li, W., He, Q., Liu, R., Zhang, Y., He, L., Tracz, A., Zhao, R., Yuan, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2487999/v1 · Cited by 1
Investigating epigenetic therapies and combinations for the treatment of cancers
O’Brien, S. W. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20620610 · Cited by 1
PRMT5 inhibition sensitizes glioblastoma tumor models to temozolomidePreprint
Onishi, S., Jayamohan, S., Chowdhury, A. K., Rivas, S. R., Otani, Y., Murphy, S. A., Rivera-Caraballo, K., Walbridge, S., Shah, A. H., Sisay, B., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5936706/v1 · Cited by 1
Self-citation
Apoptosis Pathways and Chemotherapy in Brain Tumors
Venere, M., De, K., Yoo, J. Y., & Kaur, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812100-9.00020-6
Self-citation
PRMT5 in T helper lymphocytes is essential for cholesterol biosynthesis-mediated Th17 responses and autoimmunityPreprint
Webb, L., Sengupta, S., Edell, C., Amici, S. A., Miranda, J. N., Kennemer, A. A., & Guerau‐de‐Arellano, M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/792788
The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progressionPreprint
Feng, N., Yao, B., Zhu, S., Wei, X., Chen, M., Feng, Y., Li, Z., Xu, X., Zhang, Y., Wang, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1484038/v1
Faculty Opinions recommendation of PRMT5-mediated regulation of developmental myelination.
Lu, Q. R., & Berry, K. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733672005.793570340
Let’s Get Physical: On Observing Force Perturbations of Proliferating Glioblastomal CellsPreprint
Seto, J., & Chen, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.24.525397
PRMT5 Promotes Esophageal Carcinoma Metastasis by Enhancing PAK1 PhosphorylationPreprint
Wu, G., Zou, X., Lin, Y., Meng, Y., Chen, S., Gu, Y., Guo, L., Yi, L., Dong, H., Wang, L., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2539484/v1
Role of various therapeutic targets in the treatment of glioblastoma
Maurya, R., Sood, N., Vikal, A., Khare, S., Sharma, S., Sharma, R., Patel, P., & Kurmi, B. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33319-4.00004-5
Additional file 7 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993176
Additional file 6 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993173
Additional file 3 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993161
Additional file 10 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993185
Additional file 5 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993170
Additional file 1 of The circSPON2/miR-331-3p axis regulates PRMT5, an epigenetic regulator of CAMK2N1 transcription and prostate cancer progression
Yao, B., Zhu, S., Wei, X., Chen, M.-K., Feng, Y., Li, Z., Xu, X., Zhang, Y., Wang, Y., Zhou, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19914948
Additional file 9 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993182
Additional file 1 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993155
Additional file 4 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993164
Additional file 8 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993179
Additional file 2 of Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
O’Brien, S., Butticello, M., Thompson, C. S., Wilson, B. G., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H. P., & Fedoriw, A. (2023) · Figshare · doi:10.6084/m9.figshare.23993158
Cell death pathways and chemotherapy in brain tumors
Sahu, U., Venere, M., & Kaur, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00026-7
Self-citation
Analysis of protein arginine methyltransferase 5 as a therapeutic target in triple-negative breast cancers
Vinet, M. (2019) · theses.fr (ABES) · doi:10.70675/44db51eaz962fz4c89zb7aezf28a33c80756
Analysis of the Protein Arginine Methyltransferases 1 (PRMT1) and 4 (PRMT4) in Triple-Negative Breast Cancer
Suresh, S. (2021) · theses.fr (ABES) · doi:10.70675/d0ca1237zb08dz4dbfz9d33zd98df750e43c
PRMT5 as an Epigenetic Target for Group 3 (MYC-driven) MedulloblastomaPreprint
Kumar, D., Sharma, A., Dash, A. K., Kanchan, R. K., Ding, L., Chhonker, Y. S., Shakyawar, S. K., Guda, C., Naik, G. R., Murry, D. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.09.717536
Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer
Yu, M., Das, P., Zhang, X., & Cheng, X. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70304
Self-citation
Epigenetic deregulation in adult gliomas: A key driver of molecular heterogeneity and precision oncology
Gezer, E., Charkhian, H., & Tunçer, Ş. B. (2026) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlag096
BindingDB Entry 50022921: Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.
BindingDB (2026) · UC San Diego · doi:10.7270/q2n58s7x
BindingDB Entry 50045968: Discovery of a Dual PRMT5-PRMT7 Inhibitor.
BindingDB (2016) · UC San Diego · doi:10.7270/q2q81fsz
BindingDB Entry 50049302: Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.
BindingDB (2019) · UC San Diego · doi:10.7270/q2d220xw
BindingDB Entry 50012829: Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
BindingDB (2022) · UC San Diego · doi:10.7270/q2765k17
BindingDB Entry 50018799: Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
BindingDB (2024) · UC San Diego · doi:10.7270/q24x5d1g
BindingDB Entry 50002756: Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
BindingDB (2020) · UC San Diego · doi:10.7270/q2bz68qc
BindingDB Entry 50017921: Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
BindingDB (2023) · UC San Diego · doi:10.7270/q20k2dnq
BindingDB Entry 50007159: Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
BindingDB (2021) · UC San Diego · doi:10.7270/q2sb490f
BindingDB Entry 50022533: Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
BindingDB (2025) · UC San Diego · doi:10.7270/q2p55t8z
BindingDB Entry 7890: Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
BindingDB (2017) · UC San Diego · doi:10.7270/q21v5ctr

Authors: Yan, F., Alinari, L., Lustberg, M. E., Katherine Martin, L., Cordero-Nieves, H. M., Banasavadi-Siddegowda, Y., Virk, S., Barnholtz-Sloan, J., Bell, E. H., Wojton, J., Jacob, N. K., Chakravarti, A., Nowicki, M. O., Wu, X., Lapalombella, R., Datta, J., Yu, B., Gordon, K., Haseley, A., Patton, J. T., Smith, P. L., Ryu, J., Zhang, X., Mo, X., Marcucci, G., Nuovo, G., Kwon, C.-H., Byrd, J. C., Chiocca, E. A., Li, C., Sif, S., Jacob, S., Lawler, S., Kaur, B., & Baiocchi, R. A.
Affiliations: Case Comprehensive Cancer Center (US)
Authors' Affiliations: 1Division of Hematology, Department of Internal Medicine; 2Division of Infectious Diseases, Department of Internal Medicine; Departments of 3Neurosurgery; 4Molecular and Cellular Biochemistry; 5Chemical Engineering; 6Statistics; 7Pathology; 8Radiation Oncology; and 9College of Pharmacy, The Ohio State University (OSU), Columbus; 10Case Comprehensive Cancer Center; and 11Department of Epidemiology and Biostatistics, CWRU School of Medicine, Cleveland, Ohio
Brigham and Women's Hospital (US)
Corresponding author: Kaur, Balveen
Baiocchi, Robert A.
ORCID: Yan, Fengting
Alinari, Lapo
Bell, Erica Hlavin
Jacob, Naduparambil K.
Chakravarti, Arnab
Nowicki, Michal O.
Wu, Xin
Lapalombella, Rosa
Yu, Bo
Ryu, John
Zhang, Xiaoli
Mo, Xiaokui
Marcucci, Guido
Chiocca, E. Antonio
Li, Chenglong
Lawler, Sean
Kaur, Balveen
Baiocchi, Robert A.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2014-03-13
Volume: 74
Issue: 6
Pages: 1752-1765
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-13-0884
PMC: PMC3959215
OpenAlex: W2109483913
Cited by: 180
References: 40
Citations by year: 2026: 8 · 2025: 14 · 2024: 16 · 2023: 26 · 2022: 12 · 2021: 18 · 2020: 10 · 2019: 15 · 2018: 17 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 3
FWCI: 6.15
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (TL1TR000091)
National Cancer Institute (R01CA150153, P30CA016058, P01CA163205)
National Institute of General Medical Sciences (T32GM136583)
National Institute of Neurological Disorders and Stroke (R01NS064607, R21NS071346)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
Keywords: PRMT5, protein arginine methyltransferase, glioblastoma, ST7, gene silencing, therapeutic target, prognostic factors, temozolomide, caspase-dependent apoptosis, cell migration, cell cycle arrest, patient survival, theranostic target
MeSH terms: Animals, Brain Neoplasms, Glioblastoma, Humans, Mice, Nude, Neoplasm Transplantation, Protein-Arginine N-Methyltransferases, Gene Expression, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Mice, Knockout, Tumor Suppressor Proteins, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Kaplan-Meier Estimate, Gene Knockdown Techniques, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks